GlassScriptPhysician profile
Gary B Mccallum
NPI 1205862315
$1,367.83
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.86 · 2020: $56.25 · 2021: $142 · 2022: $370 · 2023: $439 · 2024: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $516 · Travel and Lodging: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.49 |
| Travel and Lodging | $263.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $438.90 | 2022-2023 | Sonicone Clinic |
| Kerecis Limited | $274.82 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Solventum Corporation | $263.96 | 2024 | V.A.C. Dermatac, Activ.A.C., 3m Coban |
| Kci USA, INC. | $166.00 | 2021-2023 | Activ.A.C., V.A.C. Dermatac |
| Smith+Nephew, INC. | $73.61 | 2019-2021 | |
| Organogenesis INC. | $52.45 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $37.49 | 2021 | |
| Abbvie INC. | $20.35 | 2024 | |
| Janssen Pharmaceuticals, INC | $15.35 | 2020 | |
| Pfizer INC. | $12.45 | 2022 | |
| Acera Surgical, INC. | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Mccallum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.